Rasmus Holm-Jorgensen
Patrimonio netto: 41 741 $ in data 31/05/2026
Patrimonio netto: 41 741 $ in data 31/05/2026
Mr. Rasmus Holm-Jorgensen was previously employed as a Chief Financial Officer by Acrivon Therapeutics, Inc., a Chief Strategy & Portfolio Officer by Kiniksa Pharmaceuticals Ltd., and a Group Vice President & General Manager by Synageva BioPharma Corp.
He received his graduate degree from the University of Copenhagen.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 01/03/2025 | 26.088 ( 0,06% ) | 41 741 $ | 31/05/2026 |
| Società | Posizione | Fine |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Direttore Finanziario/CFO | 01/04/2025 |
Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and delivers therapeutic medicines for patients suffering from cardiovascular diseases | Fondatore | 01/04/2022 |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 01/01/2015 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Develops and manufactures biopharmaceutical products | Health Technology |
Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and delivers therapeutic medicines for patients suffering from cardiovascular diseases | Health Technology |
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops and sells precision oncology medicines | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale